Posts

Posted on

Griffon to Participate at the 21st Annual CJS Securities “New Ideas” Summer Conference

Griffon to Participate at the 21st Annual CJS Securities “New Ideas” Summer Conference

NEW YORK–(BUSINESS WIRE)–
Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) today announced it will present at the CJS Securities 21st Annual “New Ideas” Summer Conference on Tuesday, July 13, 2021. The conference will be held in a virtual format. A copy of Griffon’s investor presentation, which will be used for the conference, will be available at the time of the conference in the investor relations section of Griffon’s website (www.griffon.com).

About Griffon Corporation

Griffon is a diversified management and holding company that conducts business through wholly-owned subsidiaries. Griffon oversees the operations of its subsidiaries, allocates resources among them and manages their capital structures. Griffon provides direction and assistance to its subsidiaries in connection with acquisition and growth opportunities as well as in connection with divestitures. In order to further diversify, Griffon also seeks out, evaluates and, when appropriate, will acquire additional businesses that offer potentially attractive returns on capital.

Griffon conducts its operations through three reportable segments:

  • Consumer and Professional Products (“CPP”) conducts its operations through The AMES Companies, Inc. (“AMES”). Founded in 1774, AMES is the leading North American manufacturer and a global provider of branded consumer and professional tools and products for home storage and organization, landscaping, and enhancing outdoor lifestyles. CPP sells products globally through a portfolio of leading brands including True Temper, AMES, and ClosetMaid.
  • Home and Building Products conducts its operations through Clopay Corporation (“Clopay”). Founded in 1964, Clopay is the largest manufacturer and marketer of garage doors and rolling steel doors in North America. Residential and commercial sectional garage doors are sold through professional dealers and leading home center retail chains throughout North America under the brands Clopay, Ideal, and Holmes. Rolling steel door and grille products designed for commercial, industrial, institutional, and retail use are sold under the CornellCookson brand.
  • Defense Electronics conducts its operations through Telephonics Corporation, founded in 1933, a globally recognized leading provider of highly sophisticated intelligence, surveillance and communications solutions for defense, aerospace and commercial customers.

For more information on Griffon and its operating subsidiaries, please see the Company’s website at www.griffon.com.

Company Contact:

Brian G. Harris

SVP & Chief Financial Officer

Griffon Corporation

(212) 957-5000

Investor Relations Contact:

Michael Callahan

Managing Director

ICR Inc.

(203) 682-8311

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Landscape Manufacturing Other Manufacturing Residential Building & Real Estate Construction & Property

MEDIA:

Posted on

Maxim Integrated Plans To Announce Fiscal Fourth Quarter 2021 Results

PR Newswire

SAN JOSE, Calif., July 7, 2021 /PRNewswire/ — Maxim Integrated Products, Inc. (NASDAQ: MXIM) plans to provide a press release with fiscal fourth quarter 2021 results after market close on Tuesday, July 27, 2021. This release will be available at investor.maximintegrated.com. Due to the pending merger with Analog Devices, there will not be a conference call associated with an upcoming press release.

Should the pending merger with Analog Devices be completed on or before Tuesday, July 27, 2021, a press release will not be issued for Maxim’s fiscal fourth quarter 2021 results. Investors are requested to review our Investor Relations website for the quarterly financial highlights and SEC filings for the latest updates on the pending transaction with Analog Devices.

About Maxim Integrated
Maxim Integrated, an engineer’s engineering company, exists to solve the designer’s toughest problems in order to empower design innovation. Our broad portfolio of high-performance semiconductors, combined with world-class tools and support, delivers essential analog solutions including efficient power, precision measurement, reliable connectivity and robust protection along with intelligent processing. Designers in application areas such as automotive, communications, consumer, data center, healthcare, industrial and IoT trust Maxim to help them quickly develop smaller, smarter and more secure designs. Learn more at https://www.maximintegrated.com.

Contact:

Kathy Ta

Vice President, Investor Relations

408-601-5697

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/maxim-integrated-plans-to-announce-fiscal-fourth-quarter-2021-results-301327261.html

SOURCE Maxim Integrated Investor Relations

Posted on

10x Genomics to Report Second Quarter Financial Results on August 4, 2021

PLEASANTON, Calif., July 07, 2021 (GLOBE NEWSWIRE) — 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2019 based on publications and all of the top 20 global pharmaceutical companies by 2019 research and development spend, and have been cited in over 2,500 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 1,100 issued patents and patent applications.
  
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Media:
[email protected]

Investors:
[email protected]



Posted on

SI-BONE, Inc. Announces Publication of iFuse-3D Implant Clinical Study Results Showing Accelerated Fusion, Immediate and Sustained Clinical Improvements and Reduction in Opioid Use

There are now 95 peer-reviewed publications demonstrating the safety, effectiveness, biomechanical or economic benefits of iFuse Technology™

SANTA CLARA, Calif., July 07, 2021 (GLOBE NEWSWIRE) — SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy announced the publication of 2-year results from SALLY (Study of bone growth in the Sacroiliac Joint after Minimally Invasive Surgery with Titanium Implants, ClinicalTrials.gov NCT 03122899)1, a prospective multicenter clinical trial of the iFuse-3D™ Implant System. Clinical results at 24 months showed marked and sustained improvements in sacroiliac (SI) joint pain, patient function and quality of life that are consistent with results from three prior multicenter prospective clinical trials using the iFuse implant (RCT INSITE 2-year2, RCT iMIA 2-year3, SIFI 2-year4). Results also demonstrated a significant reduction in the proportion of study subjects taking opioids for SI joint pain (59% at baseline to 18% at 24 months). In addition, the study included three objective physical function tests (active straight leg raise, five times sit-to-stand and transitional timed up-and-go), all of which showed statistically significant improvements from baseline.

An earlier publication of 12-month results from SALLY (Patel 20205) reported radiographic analysis of CT scans showing accelerated bony bridging across the SI joint compared to the iFuse implant. 100% of treated SI joints showed bone integration to the iFuse-3D implant surface on both the sacral and iliac side, and 77% of treated joints showed bony bridging across the joint.

“These 24-month results from the SALLY study show that the 3D-printed iFuse-3D implant provides the same early and sustained clinical benefits as those demonstrated in two prior RCTs2,3 and one large multicenter prospective trial4 using the original iFuse implant,” said Vikas Patel, MD., Department of Orthopedics at University of Colorado and study principal investigator. “Furthermore, the early results from radiographic analysis of implant bone integration and SI joint bony bridging indicate that the enhanced porous surface of the iFuse-3D implant combined with the fenestrated structural design accelerates the rate of intraarticular fusion compared to the iFuse implant.”

The iFuse-3D implant is the first 3D-printed triangular titanium implant designed for fusion of the SI joint. The iFuse-3D implant has a proprietary 3D-printed surface with enhanced porosity, which mimics cancellous bone and allows for enhanced bone ongrowth and ingrowth (MacBarb 2017, Part 16). It also has a patented fenestrated structure that allows self-harvesting of bone during implant insertion that provides an excellent environment for bone through growth (MacBarb 2017, Part 27).

  1. Patel V, et al. Prospective Trial of Sacroiliac Joint Fusion Using 3D-Printed Triangular Titanium Implants: 24-Month Follow-Up. Med Devices (Auckl). 2021;14:211-216. DOI: 10.2147/MDER.S314828
  2. Polly DW, et al. Two-Year Outcomes from a Randomized Controlled Trial of Minimally Invasive Sacroiliac Joint Fusion vs. Non-Surgical Management for Sacroiliac Joint Dysfunction. Int J Spine Surg. 2016;10:28. DOI: 10.14444/3028
  3. Dengler J, et al. Randomized Trial of Sacroiliac Joint Fusion vs. Conservative Management for Chronic Low Back Pain Attributed to the Sacroiliac Joint. J Bone Joint Surg Am. 2019;101(5):400-11. DOI: 10.2106/JBJS.18.00022
  4. Duhon B, et al. Triangular Titanium Implants for Minimally Invasive Sacroiliac Joint Fusion: 2-Year Follow-Up from a Prospective Multicenter Trial. Int J Spine Surg. 2016;10:13. DOI: 10.14444/3013
  5. Patel V, et al. Prospective Trial of Sacroiliac Joint Fusion Using 3D-Printed Triangular Titanium Implants. Med Devices (Auckl). 2020;13:173-82. DOI: 10.2147/MDER.S253741
  6. MacBarb RF, et al. Fortifying the Bone-Implant Interface Part 1: An In Vitro Evaluation of 3D-Printed and TPS Porous Surfaces. Int J Spine Surg. 2017;11:105-15. DOI: 10.14444/4015
  7. MacBarb RF, et al. Fortifying the Bone-Implant Interface Part 2: An In Vivo Evaluation of 3D-Printed and TPS-Coated Triangular Implants. Int J Spine Surg. 2017;11:116-28. DOI: 10.14444/4016

About SI-BONE, Inc.
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System®. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse implant, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two randomized controlled trials, showing improved pain, patient function and quality of life resulting from treatment. There are over 95 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.

Investor Contact:
Matt Bacso, CFA
[email protected]

Media Contact:
Joe Powers
[email protected]



Posted on

Maxar Secures WorldView Legion Commitment Under Expanded Agreement with International Defense and Intelligence Customer

Maxar Secures WorldView Legion Commitment Under Expanded Agreement with International Defense and Intelligence Customer

WESTMINSTER, Colo.–(BUSINESS WIRE)–
Maxar Technologies (NYSE:MAXR) (TSX:MAXR), a trusted partner and innovator in Earth Intelligence and Space Infrastructure, today announced a contract for WorldView Legion satellite constellation capacity through an expanded agreement with a key international defense and intelligence customer.

The multi-year, $35 million contract extends the customer’s ability to directly task and download 30 cm-class satellite imagery to its ground station from Maxar’s current constellation under the Direct Access Program. This program access enables defense, intelligence and commercial customers to access the world’s most advanced Earth imaging satellites, with encrypted downlinks, committed availability and data distribution rights that fit mission needs. The contract will also provide direct access to Maxar’s next-generation WorldView Legion satellites once they enter operations, and it includes to Maxar’s 3D data suite, created from the company’s industry-leading, highly accurate satellite imagery.

“Maxar is proud to continue our two-decade partnership with this important U.S. ally,” said Tony Frazier, Maxar Executive Vice President of Global Field Operations. “Maxar’s commercial satellite imagery and 3D data suite will enhance situational awareness and decision-making for the customer’s critical government missions.”

About Maxar

Maxar is a trusted partner and innovator in Earth Intelligence and Space Infrastructure. We deliver disruptive value to government and commercial customers to help them monitor, understand and navigate our changing planet; deliver global broadband communications; and explore and advance the use of space. Our unique approach combines decades of deep mission understanding and a proven commercial and defense foundation to deploy solutions and deliver insights with unrivaled speed, scale and cost effectiveness. Maxar’s 4,400 team members in over 20 global locations are inspired to harness the potential of space to help our customers create a better world. Maxar trades on the New York Stock Exchange and Toronto Stock Exchange as MAXR. For more information, visit www.maxar.com.

Forward-Looking Statements

Certain statements and other information included in this release constitute “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) under applicable securities laws. Statements including words such as “may”, “will”, “could”, “should”, “would”, “plan”, “potential”, “intend”, “anticipate”, “believe”, “estimate” or “expect” and other words, terms and phrases of similar meaning are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties, as well as other statements referring to or including forward-looking information included in this presentation.

Forward-looking statements are subject to various risks and uncertainties which could cause actual results to differ materially from the anticipated results or expectations expressed in this presentation. As a result, although management of the Company believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. The risks that could cause actual results to differ materially from current expectations include, but are not limited to, the risk factors and other disclosures about the Company and its business included inthe Company’s continuous disclosure materials filed from time to time with U.S. securities and Canadian regulatory authorities, which are available online under the Company’s EDGAR profile at www.sec.gov, under the Company’s SEDAR profile at www.sedar.com or on the Company’s website at www.maxar.com.

The forward-looking statements contained in this release are expressly qualified in their entirety by the foregoing cautionary statements. All such forward-looking statements are based upon data available as of the date of this presentation or other specified date and speak only as of such date. The Company disclaims any intention or obligation to update or revise any forward-looking statements in this presentation as a result of new information or future events, except as may be required under applicable securities legislation.

Investor Relations Contact:

Jason Gursky

Maxar VP, Investor Relations and Corporate Treasurer

1-303-684-2207

[email protected]

Media Contact:

Turner Brinton

Director of Public Relations

1-303-684-4545

[email protected]

KEYWORDS: Colorado United States North America Canada

INDUSTRY KEYWORDS: Technology Construction & Property Contracts Satellite Other Technology Other Construction & Property Other Science Science Defense

MEDIA:

Posted on

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

LEXINGTON, Mass., July 7, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 259,550 shares of Curis common stock to fifteen new employees, with a grant date of July 1, 2021 (the “Q3 2021 Inducement Grants”).

Each of the Q3 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company’s common stock on July 1, 2021. Each stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee’s date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee’s continued service with the Company through the respective vesting dates.  Each stock option was granted as an inducement equity award outside of the Company’s Fourth Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at www.curis.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301326424.html

SOURCE Curis, Inc.

Posted on

Ramaco Resources, Inc. Announces Public Offering of Senior Unsecured Notes Due 2026

Company Release – July 7, 2021

PR Newswire

LEXINGTON, Ky., July 7, 2021 /PRNewswire/ — Ramaco Resources, Inc. (NASDAQ: METC) (“Ramaco Resources” or the “Company”) announced today that it plans to offer senior unsecured notes due 2026 (the “Notes”) in a registered underwritten public offering (the “Offering”). The Company intends to use the net proceeds from the Offering for general corporate purposes, including funding future acquisitions and investments, making capital expenditures and funding working capital. The Notes will be issued in minimum denominations of $25.00 and integral multiples of $25.00 in excess thereof.

In connection with the Offering, the Company has applied to list the Notes on the NASDAQ Global Select Market (the “NASDAQ”) under the symbol “METCL.” If approved for listing, trading on the NASDAQ is expected to commence within 30 days after the Notes are first issued.

B. Riley Securities, Inc., Ladenburg Thalmann & Co. Inc., and William Blair & Company, L.L.C. will act as joint book-running managers for the Offering. Aegis Capital Corp., The Benchmark Company, LLC and B.C. Ziegler & Company will act as co-managers for the Offering.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Notes may only be offered and sold under the Company’s registration statement on Form S-1, which has been filed with the Securities and Exchange Commission (“SEC”) but has not yet become effective. The Notes may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. A copy of the registration statement is available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus related to the Offering may be obtained from the offices of B. Riley Securities, Inc. at 1300 North 17th Street, Suite 1400, Arlington, VA 22209, by calling (703) 312–9580 or by emailing [email protected].

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Ramaco Resources’ expectations or beliefs concerning guidance, future events, anticipated revenue, costs and expectations regarding operating results, and it is possible that the results described in this news release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of Ramaco Resources’ control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. These factors include, without limitation, risks related to the impact of the COVID-19 global pandemic, unexpected delays in our current mine development activities, failure of our sales commitment counterparties to perform, increased government regulation of coal in the United States or internationally, or further decline of demand for coal in export markets and underperformance of the railroads. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Ramaco Resources does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Ramaco Resources to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements found in Ramaco Resources’ filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The risk factors and other factors noted in Ramaco Resources’ SEC filings could cause its actual results to differ materially from those contained in any forward-looking statement.

About Ramaco Resources, Inc.

Ramaco Resources, Inc. is an operator and developer of metallurgical coal in southern West Virginia, southwestern Virginia and southwestern Pennsylvania. Its executive offices are in Lexington, Kentucky, with operational offices in Charleston, West Virginia. The Company has five active mines operating from two mining complexes at this time.

News and additional information about Ramaco Resources, including filings with the Securities and Exchange Commission, are available at https://www.ramacoresources.com.

Contact:

Phone: 859-244-7455
E-mail: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/ramaco-resources-inc-announces-public-offering-of-senior-unsecured-notes-due-2026-301327345.html

SOURCE Ramaco Resources, Inc.

Posted on

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units (RSUs) to 12 new employees under Blueprint Medicines’ 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual’s entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The options have an exercise price of $87.66 per share, which is equal to the closing price of Blueprint Medicines’ common stock on July 1, 2021. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee’s continued employment on each vesting date. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee’s continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Blueprint Medicines’ 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301326702.html

SOURCE Blueprint Medicines Corporation

Posted on

AGNC Investment Corp. Announces Date for Second Quarter Earnings Release and Stockholder Call

PR Newswire

BETHESDA, Md., July 7, 2021 /PRNewswire/ — AGNC Investment Corp. (Nasdaq: AGNC) (“AGNC” or the “Company”) announced today it will report second quarter 2021 earnings after market close on July 26, 2021.  AGNC will hold a stockholder call and audio webcast on July 27, 2021 at 8:30 am ET.  Callers who do not plan on asking a question and have internet access are encouraged to utilize the free webcast at www.AGNC.com.  Those who plan on participating in the Q&A or do not have internet available may access the call by dialing (877) 300-5922 (U.S. domestic) or (412) 902-6621 (international).  Please advise the operator you are dialing in for the AGNC Investment Corp. stockholder call.

A slide presentation will accompany the call and will be available at www.AGNC.com.  Select the Q2 2021 Earnings Presentation link to download and print the presentation in advance of the stockholder call.

An archived audio of the stockholder call combined with the slide presentation will be available on the AGNC website after the call on July 27, 2021.  In addition, there will be a phone recording available one hour after the call on July 27, 2021 through August 10, 2021.  Those who are interested in hearing the recording of the presentation can access it by dialing (877) 344-7529 (U.S. domestic) or (412) 317-0088 (international), passcode 10157767.

For further information or questions, please contact Investor Relations at (301) 968-9300 or [email protected].

ABOUT AGNC INVESTMENT CORP.
AGNC Investment Corp. is an internally-managed real estate investment trust that invests primarily in residential mortgage-backed securities for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise or a U.S. Government agency.  For further information, please refer to www.AGNC.com.

CONTACT: 
Investor Relations – (301) 968-9300

Cision View original content:https://www.prnewswire.com/news-releases/agnc-investment-corp-announces-date-for-second-quarter-earnings-release-and-stockholder-call-301327271.html

SOURCE AGNC Investment Corp.

Posted on

OpenText to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, August 5, 2021

PR Newswire

WATERLOO, ON, July 7, 2021 /PRNewswire/ — Open Text Corporation (NASDAQ: OTEX), (TSX: OTEX), announced today that financial results for its fourth quarter and fiscal year 2021 will be released on Thursday, August 5, 2021 at approximately 4:00 p.m. ET.

Teleconference Call

Mark J. Barrenechea, OpenText CEO & CTO, and Madhu Ranganathan, OpenText EVP, CFO will host a conference call on August 5, 2021 at 5:00 p.m. ET to discuss the company’s financial results.


Date:

Thursday, August 5, 2021


Time:

5:00 p.m. ET/2:00 p.m. PT


Length:

60 minutes


Dial-in:

1-800-319-4610 (toll-free)
+1-604-638-5340 (international)

Investors should dial in approximately 10 minutes before the teleconference is scheduled to begin. A replay of the call will be available beginning August 5, 2021 at 7:00 p.m. ET through 11:59 p.m. on August 19, 2021 and can be accessed by dialing 1-855-669-9658 (toll-free) or +1-604-674-8052 (international) and using passcode 7298 followed by the number sign.

For more information or to listen to the call via webcast, please visit: https://investors.opentext.com/events-and-presentations.

About OpenText
OpenText, The Information Company™, enables organizations to gain insight through market leading information management solutions, powered by OpenText Cloud-Editions. For more information about OpenText (NASDAQ: OTEX, TSX: OTEX) visit opentext.com.

Copyright ©2021 Open Text. OpenText is a trademark or registered trademark of Open Text. The list of trademarks is not exhaustive of other trademarks. Registered trademarks, product names, company names, brands and service names mentioned herein are property of Open Text. All rights reserved. For more information, visit: https://www.opentext.com/who-we-are/copyright-information.

OTEX-F

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/opentext-to-report-fourth-quarter-and-fiscal-year-2021-financial-results-on-thursday-august-5-2021-301327018.html

SOURCE Open Text Corporation